

REFERENCES

1. Republic of South Africa, Department of Statistics. Media release. Recorded live births, 2020. November 11, 2021. <http://www.stats.gov.za/publications/P0305/Media%20Release%20.pdf>
2. UNESCO. (2017). Early and unintended pregnancy & the education sector (ED/IPS/HAE/2517/01 REV). Retrieved September 18, 2019, from <https://unesdoc.unesco.org/ark:/48223/pf0000251509>
3. NewAfrican. Pandemic Leads to Surge of Child Mothers in Uganda. October 27, 2021. <https://newafricanmagazine.com/27222/>
4. Federation Atlantique des Agences de Presse Africaines (FAAPA). COVID-19 rising cases of teenage pregnancy in Ghana. October 16, 2021. <http://www.faapa.info/blog/covid-19-rising-cases-of-teenage-pregnancy-in-ghana/>
5. BBC News. Why Are there Fewer Teenager Mothers in Northern Ireland October 24, 2021. <https://www.bbc.com/news/uk-northern-ireland-59001641>
6. Centers for Disease Control and Prevention (CDC). Reproductive Health: Teen Pregnancy. <https://www.cdc.gov/teenpregnancy/about/index.htm>

Received: 6 January 2022 | Accepted: 23 February 2022 | First published online: 5 March 2022

DOI: 10.1002/ijgo.14152

Obstetrics

The transfer of vaccine-generated SARS-CoV-2 antibodies into infantile circulation via breastmilk

Barbara Lebbe¹ | Marijke Reynders² | Jens T. Van Praet^{3,4}

¹Department of Obstetrics and Gynecology, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium

²Department of Medical Microbiology, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium

³Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium

⁴Ghent University, Ghent, Belgium

Correspondence

Jens T. Van Praet, Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Ruddershove 10, 8000 Brugge, Belgium.

Email: jens.vanpraet@azsintjan.be

KEYWORDS

breastmilk, COVID-19, maternal vaccination, SARS-CoV-2

Multiple studies have demonstrated the presence of vaccine-generated IgG, IgM, and IgA in breastmilk samples,^{1,2} although their protective effect for COVID-19 on the breastfed infant is currently unclear. The present study aimed to investigate the transfer of these antibodies into infantile circulation as a possible mode of transferred immunity.

This was a longitudinal cohort study, including lactating COVID-naive women who received two Pfizer BioNTech (Pfizer) BNT162b2 vaccines with a 3-week interval, and their infants. Blood samples were collected from the mothers before, and 4 and 8 weeks after, the first vaccine. The COVID-naive status was confirmed by the absence of anti-spike (S) antibodies before vaccination. Breastmilk samples were collected 4 and 8 weeks after the first vaccine. One blood sample was collected from the infant 8 weeks after the first maternal vaccine. The study was approved by the local ethical committee (advice number 2801) and written informed consent was obtained from all participants. Anti-S

SARS CoV-2 IgG (SARS-CoV-2 IgG II Quant assay; Abbott; cutoff 50 AU/ml) and Anti-S SARS CoV-2 IgM + IgA (COVID-19 ELISA IgM + IgA; Vircell; cutoff 8 O.D.) antibodies were determined, respectively, by a chemiluminescent microparticle immunoassay on the ARCHITECT i System (Abbott) and a manual ELISA, according to the manufacturer's instructions.

Samples were obtained from 12 consecutive white mothers and their infants. The demographic characteristics of all participants are shown in [Table 1](#). The results of the breastmilk and maternal serum samples are shown in [Figure S1](#). We could detect anti-S SARS CoV-2 IgM + IgA antibodies in only one of the 13 infantile serum samples, whereas none contained anti-S SARS CoV-2 IgG above the cut-off specified by the manufacturer.

In this longitudinal cohort study, we could not detect vaccine generated anti-S SARS CoV-2 IgG in serum samples obtained from infants 8 weeks after maternal vaccination. These results argue against substantial transfer of vaccine-generated antibodies into

TABLE 1 Cohort demographic characteristics

| Lactating vaccine recipients (n = 12) | |
|--|---------------------|
| Age at first vaccination (median, range) | 32.5 years (24–39) |
| First breastmilk sampling, months after delivery (median, range) | 8 m (0–26) |
| Infants of vaccine recipients (n = 13) ^a | |
| Age at blood sampling | 9 m (1–27) |
| Female sex (%) | 31 |
| Additional mode of feeding (%) | |
| Bottle feeding | 7.7 |
| Solid feeding | 69 |
| Weight at blood sampling (median, range) | 8.02 kg (4.00–14.4) |
| Length at blood sampling (median, range) | 72 cm (53.5–93.5) |

^a Two infants were twins.

infantile circulation by mode of lactation, and are in line with another study which used sampling by dried blood spots on non-specified time points after vaccination.³ Nevertheless, breastmilk IgG or IgA may be critical for neonatal protection against COVID-19 by means of other modes, such as viral neutralization at local mucosal sites.⁴ Given the transplacental transfer of vaccine-generated anti-S SARS CoV-2 IgG, vaccination against COVID-19 during pregnancy is mandatory for the transfer of antibodies into infantile circulation.

ACKNOWLEDGMENTS

The authors are indebted to Ms. Manon Verhulst for excellent technical assistance.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.

AUTHOR CONTRIBUTIONS

BL, MR and JVP designed the study. BL and MR collected the data. JVP analyzed the data and wrote the manuscript, with input from BL and MR.

DATA AVAILABILITY STATEMENT

Research data are not shared.

REFERENCES

1. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol.* 2021;225(3):303 e301-303 e317.
2. Kelly JC, Carter EB, Raghuraman N, et al. Anti-severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination. *Am J Obstet Gynecol.* 2021;225(1):101-103.
3. Schwartz A, Nir O, Toussia-Cohen S, et al. Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine. *Am J Obstet Gynecol.* 2021;225:577-579.
4. Pace RM, Williams JE, Järvinen KM, et al. Characterization of SARS-CoV-2 RNA, antibodies, and neutralizing capacity in milk produced by women with COVID-19. *mBio.* 2021;12:e03192-20.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.